What Is Lu-177 Therapy? A Patient-Friendly Guide to How It Works, What to Expect, and Whether It Might Be Right for You

An Introduction: What Is Lu-177 Therapy?

If you or someone you love has been told that prostate cancer has spread — or has stopped responding to standard treatments — your care team may have mentioned Lu-177 PSMA therapy. The name sounds complex, but the idea behind it is fairly simple: use a "smart" radioactive molecule to seek out cancer cells and destroy them from the inside, while mostly leaving healthy tissue alone.

According to MedlinePlus (NIH), Lu-177 vipivotide tetraxetan (the formal name for the most common version used in prostate cancer) works by targeting and delivering radiation directly to cancer cells, damaging and killing them. It is given intravenously — through a drip into a vein — in a hospital or clinic setting.

This therapy belongs to a class of treatments called radioligand therapy (RLT) or theranostics. It combines diagnosis and treatment in the same system: first, doctors use a related imaging agent to confirm the cancer will respond; then the treatment agent acts on those same targets.

Who May Be a Candidate?

Lu-177 PSMA therapy is mainly used for men with metastatic castration-resistant prostate cancer (mCRPC) — meaning the cancer has spread to other parts of the body and no longer responds to hormone therapy.

As outlined by MedPark Hospital, Lu-177 PSMA is specifically for patients whose tumour lesions show PSMA expression on a PSMA PET/CT scan — a special imaging test done before treatment begins. Suitability is always assessed individually, based on prior treatments, clinical symptoms, and test results.

Research is also exploring its use earlier in the disease course. The phase 3 PSMAddition trial found that adding Lu-177 PSMA-617 to standard-of-care treatment provided a statistically significant and clinically meaningful benefit for patients with PSMA-positive metastatic hormone-sensitive prostate cancer, suggesting the therapy's role may grow over time.

Not everyone will be eligible. Your oncologist will review your scan results, previous treatments, kidney function, blood counts, and overall health before recommending this path.

How Does It Work? The Science in Plain Language

Think of Lu-177 PSMA therapy as a guided missile made from medicine. It has two key parts:

• The targeting molecule (the GPS): This is designed to bind tightly to a protein called PSMA (Prostate-Specific Membrane Antigen), which sits on the surface of prostate cancer cells. Research shows that cancerous prostate tumours can express PSMA at levels often 1,000 times higher than a normal prostate cell, making it a clear target.
• The radioactive payload (the weapon): Attached to the targeting molecule is Lutetium-177, a radioactive isotope. Lu-177 gives off tiny bursts of energy (beta particles) that travel only a few millimetres — far enough to hit the tumour cell and its close neighbours, but short enough to spare most nearby healthy tissue.

Once injected into your bloodstream, the drug circulates through the body. When it reaches a prostate cancer cell displaying PSMA, the targeting molecule locks on. The Lutetium-177 then releases radiation from the inside, damaging the cancer cell's DNA and causing it to die.

This differs from external-beam radiation therapy, which aims radiation at the body from outside. Lu-177 PSMA involves internal radiation carried by a medicine — the dose starts precisely where the drug binds, at the cancer cell itself.

The PSMA PET Scan: Before Treatment Begins

Before you receive Lu-177 therapy, you will almost certainly have a PSMA PET scan. This uses a related (but much weaker) imaging agent to highlight any cancer cells that carry the PSMA target.

There are two reasons for this scan:

• To confirm that your cancer cells express PSMA at a high enough level for the therapy to work.
• To map exactly where cancer has spread in the body.

If cancer does not show up clearly on the PSMA PET scan, the therapy is unlikely to be effective and your team will look at other options. This is part of what makes Lu-177 PSMA therapy a "theranostic" — the same target used for imaging is the one used for treatment.

What Does a Typical Treatment Cycle Look Like?

Understanding the schedule can ease a lot of anxiety. Here is what most patients can expect:

• Frequency: Treatments are given approximately every 6 weeks. The landmark VISION trial, published in the New England Journal of Medicine (via NIH PMC), used a schedule of 7.4 GBq intravenously every 6 weeks for four to six cycles.
• The infusion itself: According to MedlinePlus, the injection is given slowly over 1 to 10 minutes, or may be infused over up to 30 minutes — much shorter than many chemotherapy infusions.
• On the day: You will receive the infusion under the supervision of a nuclear medicine specialist. Hydration is often provided, and you will be monitored for a period after the dose.
• After the infusion: You will be advised to drink plenty of fluids and urinate frequently. This helps flush the radiopharmaceutical from the body and reduces the amount of radiation retained in the bladder.
• Between cycles: Blood tests are done regularly to check kidney function and blood cell counts. Your response is typically assessed using PSA levels and imaging scans.

Some patients receive treatment as an outpatient and go home the same day, while others may stay overnight, depending on the facility's protocols and individual circumstances.

Potential Benefits: What Does the Research Show?

The evidence supporting Lu-177 PSMA therapy has grown steadily over the past decade. Here are key findings in plain terms:

• The VISION trial — a large, international Phase 3 study — found that radioligand therapy with Lu-177-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive mCRPC.
• Multiple publications have shown strong response rates and prolonged survival with limited adverse events in patients treated with Lu-177 PSMA.
• For PSA response — a key marker of how cancer is reacting to treatment — one study found that 79.1% of patients had a decline in PSA level eight weeks after their first cycle.
• Available evidence supports Lu-177 PSMA as a standard of care in selected mCRPC patients, and emerging research shows promising results in hormone-sensitive prostate cancer.

Responses vary from person to person. Lu-177 PSMA therapy may help slow or control the cancer, but it is not described in the evidence as a cure for metastatic prostate cancer. Your oncologist can give you the most realistic picture of what to expect for your specific situation.

Common Side Effects: What to Be Prepared For

All treatments carry some risk of side effects. Lu-177 PSMA therapy is generally considered to have a low toxicity profile compared to some other cancer treatments.

Research notes that side effects — including dry mouth, nausea, and fatigue — are common, but few are reported as severe.

Side effects patients may notice include:

• Fatigue — feeling more tired than usual
• Nausea — usually mild; anti-nausea medication can help
• Dry mouth (xerostomia) — because salivary glands also carry some PSMA, they can be mildly affected
• Bone marrow effects — a possible decrease in red blood cells, white blood cells, or platelets; your team will monitor blood counts regularly
• Kidney effects — a modest reduction in kidney function is possible over multiple cycles; regular monitoring helps catch this early

A study examining kidney and blood toxicity found that while some patients had slightly reduced function at baseline, the degree of toxicity during treatment was low and no severe toxicities occurred. Lu-177 PSMA also showed significantly fewer severe adverse events than chemotherapy in direct comparisons.

Tell your care team about any symptoms that concern you between appointments. Many side effects can be managed effectively when caught early.

Radiation Safety at Home: What You and Your Family Need to Know

One of the most common worries patients have is: "Will I be radioactive? Is it safe to be around my family?"

This is a fair and important question. After treatment, a small amount of radiation does continue to leave your body — mainly through urine — for a period of time. Radiation continues to be emitted from your body for up to one month, which is why some simple precautions are needed.

The key principle is straightforward: radiation exposure drops quickly with time and distance. Your care team may advise the following precautions:

• Flushing the toilet twice after using the bathroom for the first few days
• Sleeping alone or keeping distance from a partner for a few days after treatment
• Limiting close contact (within 2 metres) with young children and pregnant women, especially in the first few days
• Avoiding crowded public transport on the day of treatment
• Washing hands thoroughly after using the bathroom

Research measuring actual radiation exposure to family members found it to be minimal, with most family members receiving effectively zero measurable dose. Studies have confirmed that standard safety precautions allow patients to maintain normal social contacts, which matters for wellbeing and recovery.

Your care team will give you a personalised written list of precautions before you go home. Follow these closely — they are there to protect the people you care about.

Quality of Life During Treatment

Many patients want to know: "What will my daily life look like during treatment?"

Because treatments are spaced six weeks apart and the infusion itself is brief, many men are able to maintain a reasonable quality of life between cycles. Fatigue is the most commonly reported issue — planning rest and light activity around treatment days can help. Staying well hydrated, eating well, and keeping your care team informed about how you feel all play a role in day-to-day wellbeing.

Some patients find reassurance in the targeted nature of the therapy, knowing the radiation is going directly to cancer cells. Others find the periodic hospital visits manageable compared to more intensive treatment schedules. Your experience may differ, and it is worth talking openly with your oncologist and nurse about what support is available to you.

Looking Ahead: A Reason for Measured Hope

Lu-177 PSMA therapy is a meaningful step forward in treating advanced prostate cancer. Clinical evidence suggests it may help slow disease progression, reduce PSA levels, and extend survival for carefully selected patients.

Research is ongoing. New trials are studying its use at earlier stages of disease, in combination with other therapies, and with refined dosing strategies. The field of radioligand therapy is growing quickly, and what is possible today may be only the beginning.

If you are exploring whether this therapy might be right for you, the most important next step is an honest, informed conversation with your oncologist or a specialist in nuclear medicine or theranostics.

---

When to Talk to Your Doctor

Speak with your oncologist or care team if:

• You have been diagnosed with metastatic or advanced prostate cancer that has not responded to hormone therapy
• You have had a PSMA PET scan and want to understand what the results mean for your treatment options
• You are experiencing significant side effects during or between treatment cycles
• You have concerns about radiation safety for family members, particularly children or pregnant relatives
• You want to know about clinical trials that may give you access to Lu-177 therapy or newer related treatments

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.